Opioid Therapies and Cytochrome P450 Interactions

被引：50

作者：

Gudin, Jeffrey ^{[1
]}

机构：

[1] Englewood Hosp & Med Ctr, Pain Management & Wellness Ctr, Englewood, NJ 07631 USA

来源：

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT | 2012年 / 44卷 / 06期

关键词：

Adverse drug reactions; cytochrome P450; CYP3A4; CYP2D6; drug-drug interactions; inhibitor; inducer; metabolism; prodrug; substrate; opioids; DRUG-DRUG INTERACTIONS; ST-JOHNS-WORT; CAFFEINE METABOLISM; PHARMACOGENETICS; INHIBITION; CYP2D6; PAIN; VARIABILITY; HYDROCODONE; OXYMORPHONE;

D O I：

10.1016/j.jpainsymman.2012.08.013

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Adverse drug reactions are common and associated with substantial economic and human costs. Particularly among older adult populations, preventable adverse drug reactions are often caused by drug-drug interactions. All analgesics have side effect profiles and many have known drug-drug interactions. Opioids are recognized as a necessary option for managing moderate-to-severe pain, yet many opioid side effects can be enhanced by metabolic interactions within the liver, involving other drugs, diseases, or genetics. J Pain Symptom Manage 2012; 44: S4-S14. (C) 2012 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

引用

页码：S4 / S14

页数：11

共 61 条

[1] Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways [J].

Adams, M ;

Pieniaszek, HJ ;

Gammaitoni, AR ;

Ahdieh, H .

JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (03) :337-345

[2] A haplotype map of the human genome [J].

Altshuler, D ;

Brooks, LD ;

Chakravarti, A ;

Collins, FS ;

Daly, MJ ;

Donnelly, P ;

Gibbs, RA ;

Belmont, JW ;

Boudreau, A ;

Leal, SM ;

Hardenbol, P ;

Pasternak, S ;

Wheeler, DA ;

Willis, TD ;

Yu, FL ;

Yang, HM ;

Zeng, CQ ;

Gao, Y ;

Hu, HR ;

Hu, WT ;

Li, CH ;

Lin, W ;

Liu, SQ ;

Pan, H ;

Tang, XL ;

Wang, J ;

Wang, W ;

Yu, J ;

Zhang, B ;

Zhang, QR ;

Zhao, HB ;

Zhao, H ;

Zhou, J ;

Gabriel, SB ;

Barry, R ;

Blumenstiel, B ;

Camargo, A ;

Defelice, M ;

Faggart, M ;

Goyette, M ;

Gupta, S ;

Moore, J ;

Nguyen, H ;

Onofrio, RC ;

Parkin, M ;

Roy, J ;

Stahl, E ;

Winchester, E ;

Ziaugra, L ;

Shen, Y .

NATURE, 2005, 437 (7063) :1299-1320

[3]

American Society of Health-System Pharmacists (ASHP), 2002, TOP PAT CONC 2002 OM

[4] Relationships among morphine metabolism, pain and side effects during long-term treatment: An update [J].

Andersen, G ;

Christrup, L ;

Sjogren, P .

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 25 (01) :74-91

[5] Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study [J].

Andreassen, Trine Naalsund ;

Eftedal, Ingrid ;

Klepstad, Pal ;

Davies, Andrew ;

Bjordal, Kristin ;

Lundstrom, Staffan ;

Kaasa, Stein ;

Dale, Ola .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (01) :55-64

[6]

[Anonymous], 2010, OX PACK INS

[7]

[Anonymous], 2000, ERR IS HUMAN BUILDIN

[8] EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision [J].

Attal, N. ;

Cruccu, G. ;

Baron, R. ;

Haanpaa, M. ;

Hansson, P. ;

Jensen, T. S. ;

Nurmikko, T. .

EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 (09) :1113-E88

[9] Polypharmacy in the Elderly Maximizing Benefit, Minimizing Harm [J].

Ballentine, Noel H. .

CRITICAL CARE NURSING QUARTERLY, 2008, 31 (01) :40-45

[10]

Brennan TA, 2004, QUAL SAF HEALTH CARE, V13, P145, DOI 10.1136/qshc.2002.003822

← 1 2 3 4 5 6 7 →